Israel Active

US-based Jarrow Formulas has launched its supplement PS-PA Synergy, which is based on Lipogen PSPA, developed by Israel’s Lipogen. Lipogen PSPA has been clinically shown to alleviate stress response and improve cognition.

Israel’s Kyma Medical Technologies has developed a radio frequency-based technology device to monitor fluids in the lungs – an early sign of congestive heart failure. Kyma has just been acquired by US medical device company ZOLL for a minimum of $35 million.

Genetics experts at Jerusalem’s Shaare Zedek Medical Center have devised a patent-pending process to screen a fetus for genetic diseases using a blood sample from the mother. It is the first that can detect genetic mutations from both the father and mother’s DNA.

The United States Patent and Trademark Office has approved a patent from Israel’s Oramed for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.” The patent is the basis for Oramed’s ORMD-0801 oral insulin for the early treatment of types 1 and 2 diabetes.

Israel’s Ilex Medical has won a tender issued by the South African National Blood Service (SANBS) for its Panther blood testing systems to detect and identify viruses.

Israel’s EarlySense is launching its “smart bed” solution myEarlySense. The “under the mattress” sensors record data on how you are sleeping, such as tossing, turning, waking, sleeping, breathing and heart rates. It can also turn on heaters and make the coffee.

IBM Israel has granted Israel’s Teva access to its Watson supercomputing Health Cloud program. Teva plans to use the global technology platform to design treatments for millions of people who suffer from chronic conditions like asthma, migraine, and pain.

Technion scientists have discovered that when the HIV virus encounters resistance, it looks for detours. It then mutates and replicates itself, like a Trojan horse, exploiting redundancy in the DNA of host cells.

Further to a previous newsletter, scientists from Israel’s Technion are the only team working for European research consortium BeyondSeq on early diagnosis of cancer. They are using tiny silicon “nanopore” scanners to detect molecular DNA biomarkers in cancer cells.

Israel’s Micromedic Technologies, has identified several new genetic markers for predicting BRONJ (necrosis of the jawbone). BRONJ is a side effect of intravenous treatments in cancer and osteoporosis patients.